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A human placenta cDNA library was screened for insulin-like growth factor II (IGF-II). Four clones were 
selected, which exhibited an IGF-II cDNA coding sequence identical to those previously described for hu- 
man adult liver IGF-II cDNA. Extensive sequence diversity was observed in the S-non-coding region, prob- 
ably resulting from differential intron splicing. 
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1. INTRODUCTION 
The insulin-like growth factors (IGF) or 
somatomedins represent a family of polypeptides 
which have growth-promoting and insulin-like 
metabolic effects [l]. cDNA sequences encoding 
human IGF-I and IGF-II, and part of each IGF 
gene have been described [2-121. A single IGF-II 
gene is present on chromosome 11 close to the in- 
sulin gene [lO,l 11. The variability of the IGF-II 
mRNA may be attributed mostly to differential 
gene splicing in the 5 ‘-non-coding region, de- 
pending on tissue and stage of development 
[7-121. 
with the cDNA sequence described for human 
adult liver [7,9], differences emerged, particularly 
in the 5’-non-coding region, but three of the 
cDNAs had sequences which were homologous 
with those of the rat liver cell line, BRL 3A 181, or 
contained a sequence identical to that described for 
human hepatoma cell, HepG2 [12]. 
Finally, one of the cDNA clones contained a 
5 ’ -non-coding region not previously described. 
2. MATERIALS AND METHODS 
2.1. RNA isolation and cDNA synthesis 
IGF-II is synthesised by various tissues and 
seems to be predominant during fetal life [ 131. We 
therefore screened a human placenta cDNA library 
with IGF-II specific probes and analysed the se- 
quence of four cDNAs in detail. When compared 
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Human term placenta was washed extensively, 
within 15 min of delivery, in 20 mM Tris-HCI (pH 
7.4), 50 mM KCl, 10 mM MgCL, 100 mM NH&I, 
0.5 mM EDTA, and stored at -80°C. RNA was 
extracted using the guanidinium salt procedure, 
enriched in poly(A)+ RNA on oligo(dT)-cellulose, 
then first- and second-strand synthesis and S1 
digestion were performed as in [5]. 
2.2. Construction and screening of human cDNA 
library 
The nucleotide sequence presented here has been sub- The library was constructed using a synthetic 
mitted to the EMBL/GenBank database under the acces- adaptator and screened as described [5]. cDNA 
sion number YO0693 was integrated within the one EcoRI restriction site 
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in the Cl gene of hgtl0. The library had a complex- 
ity of 2 x lo6 recombinants. Screening was done by 
plating 5 x lo3 pfu per dish (0 130 mm) on a lawn 
of E. coli POP 101. Nitrocellulose filters were 
hybridised at 50°C overnight in buffer containing 
1 M NaCI, 0.1% SDS, 10 mM Tris-HCl (pH 7.5), 
0.05% pyrophosphate, 4 x Denhardt’s solution 
(1 x Denhardt’s = 0.02% Ficoll, 0.02% bovine 
serum albumin, 0.02% polyvinyl pyrrolidone), 5% 
dextran sulfate, and labelled probe (lo6 cpm/ml 
buffer). The filters were washed at 42°C in 3 x 
SSC (1 x SSC = 150 mM NaCl, 15 mM Na citrate, 
pH 7), 0.1% SDS for 3 x 10 min and 
autoradiographed with intensifying screens. 
2.3. DNA probes 
The human placenta cDNA library was screened 
for IGF-II with synthetic oligonucleotides com- 
plementary to the sequence of human IGF-II 
mRNA [7,9] encoding amino acids - 23 to - 17 
(probe a, N = 21); 56 to 61 (probe b, N = 17) and 
76 to 82 (pfobe c, N = 21) (fig.2). These probes 
were 5’-end-labelled using [r-32P]ATP (3000 Ci/ 
mmol; Amersham, England), and T4 polynucleo- 
tide kinase. We also used the BarnHI-EcoRI 
restriction fragment (666 base pairs) of the human 
adult liver IGF-I cDNA [5] which contains the en- 
tire coding sequence. This fragment was labelled 
by nick translation using [a-32P]dATP (3000 Ci/ 
mmol; Amersham, England). 
2.4. DNA sequence analysis 
cDNA inserts were sequenced using both Ml3 
and IGF-II specific oligonucleotides to prime the 
dideoxy-chain-terminating reaction. The strategy 
followed for each of the clones is outlined in fig. 1. 
Oligonucleotide d was complementary to 
nucleotide sequence-encoding amino acids 
119-123 (fig.2B). 
3. RESULTS 
From the initial 160000 recombinants screened 
with probe c, six were selected for further 
hybridisation. Two of them (P35, P44) gave a 
signal with oligonucleotide b (P35) or cross- 
hybridised with a nick-translated IGF-I cDNA 
probe (P35, P44; fig.1). The sequence of the 
EcoRI inserts for P35 and P44 (663 and 123 bp, 
respectively) is shown in fig.2. The region coding 
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Fig. 1. Schematic representation of the four human 
placental cDNA inserts encoding IGF-II (clones P22, 
P35, P44) and an IGF-II variant (clone P21). Regions 
coding for the signal peptide (PRE), and the B, C, A, D 
and E domains are depicted by open boxes, the 5’- and 
3’-untranslated regions being indicated by thin lines. 
The positions of the synthetic oligonucleotides (a-d) 
complementary to the nucleotide sequence of mRNA are 
indicated. The strategy for DNA sequence determination 
is indicated below each of the clones sequenced. Zigzag 
lines symbolise Ml3 arms, open squares represent 
primers (universal sequencing primer, oligonucleotide a, 
c and d) used for chain elongation, and the horizontal 
arrows indicate the direction and extent of sequence 
determinations. B29 signifies the nucleotide sequence 
variation in the IGF-II variant cDNA described by 
Jansen et al. [9]. 
for the precursor of IGF-II was identical to that 
described in [7,9]. However, the sequence cor- 
responding to the 5 ’ -non-coding exon, which ends 
seven nucleotides before the ATG initiator at 
amino acid position - 24, varied considerably 
when different IGF-II cDNAs were compared 
(fig.2). For instance, this part of the sequence in 
P35 did not correspond to the structure published 
for human adult liver [7,9] but matched the se- 
quence described for the rat liver cell line, BRL 3A 
[8,14,15]. 
A second screening of 190000 recorubinants 
from the same library was carried out with an 
oligonucleotide closer to the 5 ‘-end in the cDNA 
sequence (probe a, fig. 1). The structure of the two 
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Fig.2. Nucleotide 
AGC AAT CGG AAG TGA GCAAAACTGCCGCAAGTCTGCAGCCCGGCGCCACCATCCTGCAGCCTCCTCCTGACCACGGACGTTTCCATCAGGTTCCATCC 647 
663 
sequence of the human placental cDNA inserts encoding IGF-II and an IGF-II variant. (A) _ ._ 
Comparison of the nucleotide sequences of the 5’-untranslated regions of the three IGF-II cDNA clones (P35, P22, 
P21). The sequences were identical over six nucleotides after the initiator ATG, then diverged after the splice site 
(indicated by vertical arrows). The simple trinucleotide repeat (P21) is underlined (dashed line). Asterisks indicate the 
stop codons, and Met -24 the ATG codon at which translation starts. (B) Nucleotide and deduced amino acid 
sequences of IGF-II cDNA insert P35. The cDNA strand presented is homologous to the IGF-II mRNA. The number 
of the nucleotide at the end of each line is indicated. The amino acid sequence shown is numbered from the amino- 
terminus of the IGF-II molecule. The amino acids preceding mature IGF-II are shown as negative numbers. The region 
corresponding to the 67 amino acid residues of IGF-II is boxed. The asterisks indicate the termination codon (TGA). 
The underlined nucleotides designate the sequence complementary to synthetic oligonucleotides (a-d) used as probes 
or primers. The sequence of clone P44 is indicated between D and Q . The 3 ‘-end of the P21 and P22 cDNA inserts 
is indicated by 4. Their 5’-end is shown in panel A. In the B domain, the sequences of P22-P35 and P21 diverge; the 
amino acids and nucleotides which correspond are bracketed. 
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isolates, P21 and P22, with insert sizes of 580 and 
423 bp, respectively, is described in fig.2. P22 had 
a coding region identical to that of P35. The se- 
quence’ corresponding to the first exon, extending 
107 nucleotides upstream of the ATG initiator, 
confirmed the homology with the IGF-II cDNA 
described for the rat liver cell line, BRL 3A 
[8,14,15], as already observed in the case of P35. 
However, a different sequence was observed in the 
first exon of P21. This region resembled none of 
the previously described IGF-II cDNAs and con- 
tained a repeated CCT trinucleotide 35 nucleotides 
upstream of the ATG initiator. The coding region 
of P21 corresponded to the B29 IGF-II variant 
cDNA [9], which uses an alternative splice site be- 
tween the first two coding exons. 
4. DISCUSSION 
The coding sequence of human placental IGF-II 
RNA is identical to that described previously for 
the messenger isolated from human liver [7,9]. 
However, the sequence of the 5 ‘-non-coding 
region ending seven nucleotides before the ATG 
initiator exhibits extensive variability, not only 
from one tissue to another, but also within the 
messenger population of a particular organ, such 
as the liver or placenta. The 5 ‘-end of some of 
these clones was homologous with one of those 
found in rat liver cell line (BRL 3A) cDNA 
[8,14,15]. This exon, which has been mapped in 
the IGF-II gene region of chromosome 11 
[8,11,14], could be transcribed not only in human 
placental, but also in human hepatoma cell line 
HepG2, IGF-II cDNA [12]. 
In addition, one clone (P21) contained a se- 
quence in this region which has not been described 
before. A structure of repeated trinucleotides was 
found at a distance of 35 nucleotides upstream of 
the start of the coding region within the IGF-II 
cDNA. This sequence is not derived from the in- 
tron preceding the first coding exon [1 11, which 
would have indicated incomplete processing of the 
primary transcript. This suggests that an exon ex- 
ists in addition to those already described 
[7-12,141. Regions of simple repetitive DNA se- 
quences in the vicinity of structural genes have 
been found in other gene families, whether in the 
5 ’ -flanking region [ 16- 191, intervening sequences 
120-221 or satellite DNA [23]. It remains to be 
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established whether these short CCT repeats are in 
any way related to the regulation of IGF-II gene 
expression. The coding sequence of P21 clone with 
this simple DNA repeat contains the B29 IGF-II 
variant (fig.2) described by Jansen et al. [9]. These 
results show that the selection of the 5 ‘-non- 
coding region is regulated independently of the 
alternative splicing of B29 IGF-II variant mRNA. 
The IGF-II gene, which is present as a single 
copy on the human genome [lo, 111, is generally 
transcribed in messengers with an identical coding 
region but with different 5 ’ -terminal non-coding 
sequences [7-9,11,12,14,15]. It would seem that, 
in eucaryotic systems, transcription must be in- 
itiated from different sites [24-261 or else the 
primary transcript is processed in more than one 
way [27]. Recent findings concerning the IGF-II 
gene indicate that both mechanisms occur. In the 
case of the rat, two types of promoter region have 
been described [14,15], and the promoter used in 
adult human tissues has been shown to differ from 
that used in fetal tissue [ 121. An alternative splicing 
mechanism generating a different mature 
messenger has been described for a cDNA variant 
of IGF-II [9,11]. The structure of the 5 ‘-non- 
coding region described here for the clone, P21, 
may result from additional promoter regions 
upstream in the gene, or from variations in the 
processing of the transcript. Structural domains of 
a given protein are often encoded by individual ex- 
ons [19] and to this extent one can only speculate 
as to the reasons for heterogeneity in the 5 ’ -non- 
coding sequence of a single messenger. One 
possibility might be that it reflects the use of multi- 
ple promoters as a mode of regulating gene activity 
[ 14,15,24]. Alternatively, the stability [28,29] or 
translation efficiency [27,30] of the mature 
messenger may be affected by this heterogeneity. 
In the case of the IGF-II gene, initiation of 
transcription and processing of the primary 
transcript are apparently not regulated by single, 
clearly defined mechanisms, as is usually observed 
for eucaryotic genes. 
The biological significance of this phenomenon 
remains an open and intriguing question. 
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